Please sign in to follow a disease.
Endocrine system disorder
MONDO:0005151A disease involving the endocrine system.
Also known as: disease of endocrine system, disease or disorder of endocrine system, disorder of endocrine system, endocrine disease, endocrine disorder, endocrine system disease, endocrine system disease or disorder, endocrine system disorder
10741 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patien…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could earlier testing for pregnancy diabetes prevent complications?
Disease control TerminatedThis trial investigates whether screening for gestational diabetes earlier in pregnancy (at 18-20 weeks instead of the usual 24-28 weeks) and providing prompt lifestyle advice and medication if needed can reduce complications such as large babies, C-sections, and high blood press…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common blood pressure pill boost radiation against tough pancreatic tumors?
Disease control TerminatedThis early-phase study tests whether adding losartan (a blood pressure medicine) to a shorter, higher-dose radiation treatment can help people with pancreatic cancer that is hard to remove surgically. The main goal is to check for side effects and find the safest dose. About 22 a…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a vitamin d pill help kids with kidney disease avoid dialysis?
Disease control TerminatedThis phase 3 trial compares two oral vitamin D therapies—Hectorol (doxercalciferol) and Rocaltrol (calcitriol)—in children aged 5 to 18 with chronic kidney disease stages 3 or 4 who have high parathyroid hormone levels but are not yet on dialysis. The main goal is to see if Hecto…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Radioactive lipiodol takes aim at inoperable liver tumors
Disease control TerminatedThis phase II trial tests a targeted radiation therapy called 188Re-SSS lipiodol for people with liver cancer that cannot be surgically removed. The treatment delivers radiation directly to the tumor through the liver's blood vessels. The study aims to see how many patients' tumo…
Phase: PHASE2 • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control TerminatedThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Liquid vs crushed pills: which works better for babies with low thyroid?
Disease control TerminatedThis study compared a liquid form of thyroid medication (Tirosint-SOL) to crushed tablets in 34 infants with congenital hypothyroidism. The goal was to see which form helps maintain normal thyroid hormone levels more easily. However, the study was stopped early, so firm conclusio…
Phase: PHASE4 • Sponsor: IBSA Institut Biochimique SA • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immunotherapy combo for liver cancer shows early promise but trial halted
Disease control TerminatedThis phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) given before and after a procedure called electroporation for people with advanced hepatocellular carcinoma (liver cancer) that could still be treated with curative intent. The study aimed to see if adding nivolu…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental cancer drug tested in early trial, but study stopped early
Disease control TerminatedThis early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cocktail takes on tough pancreatic cancer
Disease control TerminatedThis early-phase trial is testing whether adding two immunotherapy drugs (botensilimab and balstilimab) to a strong chemotherapy mix plus two oral medications (chloroquine and celecoxib) can help people with metastatic pancreatic cancer that hasn't been treated yet. The study inv…
Phase: PHASE1 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New chemo combo targets Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug debio 0123 tested in early trial
Disease control TerminatedThis early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat tumors in early trial
Disease control TerminatedThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New radiation approach aims to treat liver tumors in patients with damaged livers
Disease control TerminatedThis phase I trial tested radiation therapy in 36 patients with liver cancers (hepatocellular carcinoma, cholangiocarcinoma, or metastases) who also have impaired liver function from cirrhosis, chemotherapy, or surgery. The goal was to find the safest dose and understand side eff…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Ovarian cancer combo trial halted early
Disease control TerminatedThis study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Liver cancer drug combo vs. local therapy: trial ends early
Disease control TerminatedThis study aimed to compare two standard treatments for people with large intermediate-stage liver cancer that cannot be surgically removed. One group would receive a combination of two immunotherapy drugs (atezolizumab and bevacizumab), while the other would receive local treatm…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer therapy targets tough tumors with radioactive precision
Disease control TerminatedThis early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Pancreatic cancer radiation combo trial cut short
Disease control TerminatedThis study looked at whether adding a precise type of radiation (stereotactic body radiation therapy) to standard chemotherapy could better control pancreatic cancer that has spread to only a few spots in the body. The trial planned to enroll patients with limited metastases, but…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hospital metformin debate: keep or stop? small study offers few answers.
Disease control TerminatedThis study looked at whether people with type 2 diabetes should continue taking their usual metformin medication while hospitalized. The goal was to see if it helped control blood sugar, caused stomach issues, or affected how long patients stayed. Only 22 people took part before …
Phase: PHASE4 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Liver transplants for HIV-HCV patients: a feasibility study
Disease control TerminatedThis study aimed to see if liver transplantation is possible and safe for people infected with both HIV and hepatitis C. Fifteen patients were enrolled to track survival, virus behavior, and drug interactions after transplant. The goal was to understand how these two viruses inte…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a glucose monitor boost diabetes education for newly diagnosed patients?
Disease control TerminatedThis study tested whether using a Freestyle Libre 2 continuous glucose monitor for 28 days, along with standard therapeutic education, helps people recently diagnosed with type 2 diabetes improve their blood sugar control. The trial enrolled 27 adults diagnosed within the past ye…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney drug trial for infants and toddlers halted early
Disease control TerminatedThis study tested a liquid medicine called paricalcitol in children aged 0 to 9 years with severe kidney failure who are on dialysis. The goal was to see if it safely lowers high parathyroid hormone levels, a common complication. The trial was stopped early after enrolling only 2…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smartphone system aims to automate insulin delivery for type 1 diabetes
Disease control TerminatedThis study tests an automated insulin delivery system for adults with type 1 diabetes. The system uses a smartphone connected to a continuous glucose monitor and insulin pump to help keep blood sugar levels in a healthy range, especially overnight. Ten participants compare the au…
Phase: NA • Sponsor: Sue Brown • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hepatitis b drug combo trial halted early
Disease control TerminatedThis early-stage study tested a new experimental drug called GSK3965193, alone and in combination with another drug (bepirovirsen), for people with chronic hepatitis B. The goal was to see if the combination could lower hepatitis B virus levels and possibly lead to a sustained re…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising drug trial for rare pancreatic cancer stopped early
Disease control TerminatedThis study tested whether the drug surufatinib could help prevent pancreatic neuroendocrine tumors from coming back after surgery. The trial was planned for many participants but was stopped early with only 6 people enrolled. Because it ended early, we don't have clear answers on…
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental combo therapy shows promise in advanced cancers, but trial halted early
Disease control TerminatedThis study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
PBC drug combo safety check ends early
Disease control TerminatedThis study looked at the long-term safety of a fixed-dose combination of two drugs (obeticholic acid and bezafibrate) for people with primary biliary cholangitis (PBC), a chronic liver disease. It enrolled 62 adults who had already been taking the combination in earlier studies. …
Phase: PHASE3 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Cancer combo trial halted early after enrolling only 5 patients
Disease control TerminatedThis study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis phase 3 trial tested a combination of two targeted drugs, alpelisib and olaparib, against standard chemotherapy in 358 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum-based chemotherapy. The study only included women without a BRCA …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Heart drug fails to prove benefit for lung failure patients in early-stop trial
Disease control TerminatedThis study tested whether giving the heart medication metoprolol through a vein could help people with severe lung failure (ARDS) in the ICU. The goal was to see if it helped them breathe without a machine for more days. However, the trial was stopped early and only 14 people too…
Phase: PHASE3 • Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Cancer drug combo tested for rare gene mutation – but trial stopped early
Disease control TerminatedThis study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enroll…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets common cancer mutation in early trial
Disease control TerminatedThis early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered virus takes on cancer in first human trial
Disease control TerminatedThis early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Hospital hep c treatment aims to cure drug users
Disease control TerminatedThis study tested giving hepatitis C treatment to people who inject drugs while they were already in the hospital for other infections. The goal was to cure their hepatitis C and make sure they stayed connected to care afterward. The study was stopped early, but it included 21 pa…
Phase: NA • Sponsor: Kirby Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough bile duct cancers
Disease control TerminatedThis study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…
Phase: PHASE2 • Sponsor: Lisata Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Pfizer's new cancer pill tested in advanced tumors – study halted early
Disease control TerminatedThis early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Liver cancer radiation trial halted after just one patient
Disease control TerminatedThis study aimed to see if adding focused radiation to standard chemotherapy helps people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Only one person enrolled before the trial was stopped early, so no meaningful conclusions can…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a daily injection reshape bodies of HIV patients?
Disease control TerminatedThis study looked at whether tesamorelin (Egrifta), a daily injection that boosts growth hormone, can improve body composition in people with HIV who have excess belly fat (lipodystrophy). Six participants received the drug for up to 12 months, with researchers measuring liver fa…
Phase: PHASE4 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental diabetes drug trial halted early
Disease control TerminatedThis study tested an experimental drug called TOL-3021 in people with type 1 diabetes to see if it could help preserve the body's ability to produce insulin. The trial enrolled 78 participants aged 12 to 41 who had been diagnosed within the last 5 years. The study was terminated …
Phase: PHASE2 • Sponsor: Tolerion, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
Disease control TerminatedThis phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cell therapy targets tough cancers, but trial ends early
Disease control TerminatedThis early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Diabetes drug trial halted: could BMF-219 have boosted insulin?
Disease control TerminatedThis study tested an experimental drug called BMF-219 in people with type 1 diabetes to see if it could help their bodies produce more insulin. The trial was stopped early, but researchers planned to compare insulin levels between those who got the drug and those who got a placeb…
Phase: PHASE2 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control TerminatedThis study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo trial for tough pancreatic cancer shows early promise
Disease control TerminatedThis early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 adults with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and understand side effects. The study was stopped early, so r…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control TerminatedThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
CRISPR's diabetes cell therapy trial ends early
Disease control TerminatedThis early-stage study tested a new treatment called VCTX211 for people with type 1 diabetes. The goal was to see if implanting these special cells could help the body make insulin and reduce the need for insulin shots. Only 5 people took part, and the study was stopped early. Th…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising diabetes delay study halted due to lack of participants
Disease control TerminatedThis study tested a low dose of a drug called ATG to see if it could delay or prevent type 1 diabetes in people at high risk. Only 2 people enrolled, so the study was stopped early. The goal was to measure how long it took for participants to develop full-blown diabetes.
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug A3907 tested for rare liver disease, study halted early
Disease control TerminatedThis study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Liver cancer immunotherapy study halted early
Disease control TerminatedThis study tested two immunotherapy drugs (durvalumab and tremelimumab) in people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely shrink tumors and control the disease without causing organ rejection. Only 8 people took par…
Phase: PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental lung cancer combo trial halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called Debio 0123 combined with standard chemotherapy (carboplatin and etoposide) in 34 adults with small cell lung cancer that had returned after prior treatment. The main goal was to find a safe dose and check for side effects.…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Meals and exercise program aimed at managing diabetes in pregnancy
Disease control TerminatedThis study tested a community-based program called Meals 4 Moms for pregnant women with gestational diabetes. Participants received tailored meals, education, and activity monitoring. The goal was to see if the program was practical and acceptable. Only 8 women were enrolled befo…
Phase: NA • Sponsor: UConn Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control TerminatedThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental liver drug INT-787 studied for severe alcohol hepatitis
Disease control TerminatedThis study tested a drug called INT-787 in 67 people with severe alcohol-associated hepatitis, a serious liver condition. The trial was a phase 2a proof-of-concept study, but it was terminated early. Researchers were looking at safety, how well the drug works, and how the body pr…
Phase: PHASE2 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Glow-in-the-dark dye could help surgeons save tiny glands during thyroid surgery
Disease control TerminatedThis study tested whether a fluorescent dye called indocyanine green can help surgeons find and protect the parathyroid glands during thyroid or parathyroid surgery. The dye is injected into the bloodstream and makes the glands glow under a special camera. The trial enrolled 417 …
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Cancer combo trial halted early: what we learned
Disease control TerminatedThis study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo aims to control resistant liver cancer
Disease control TerminatedThis study tested whether adding an experimental drug (VIC-1911) to the standard drug lenvatinib could help people with liver cancer that no longer responds to lenvatinib alone. Only 5 people were enrolled before the study was stopped early. The goal was to see if the combination…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Diet and drug combo aim to tame tumor side effects
Disease control TerminatedThis study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…
Phase: PHASE1 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Tailored cancer therapy put to the test
Disease control TerminatedThis study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Lung cancer immune cell therapy study stopped early after just 2 patients
Disease control TerminatedThis study tested a treatment called GT201, which uses immune cells taken from a patient's own tumor to attack advanced lung cancer. It was designed for adults aged 18-70 with non-small cell or small cell lung cancer that had stopped responding to standard treatments. The study w…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Lung cancer drug combo trial halted early
Disease control TerminatedThis study tested a new combination of cancer drugs (bemarituzumab plus anlotinib) against a standard treatment (tislelizumab) for people with extensive-stage small cell lung cancer. The goal was to see if the new combo could delay cancer growth or improve survival. However, the …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Liver cancer drug trial halted after just 3 patients
Disease control TerminatedThis study tested the drug lenvatinib in people whose liver cancer came back after a liver transplant. The goal was to see if the drug could shrink tumors. Only 3 people joined before the study was stopped early, so we have very limited information on how well it works.
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Antibiotic vancomycin tested as PSC treatment – trial stopped early
Disease control TerminatedThis study tested whether the antibiotic vancomycin, taken by mouth, is safe and effective for adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were randomly assigned to receive vancomycin or a placebo. The main goal was to see if van…
Phase: PHASE2, PHASE3 • Sponsor: Elizabeth Carey • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Diabetes drug adherence study halted after just one participant
Disease control TerminatedThis study aimed to see if following the exact dosing instructions for oral semaglutide helps control blood sugar in people with type 2 diabetes who are already on metformin. Only one person enrolled before the study was stopped early. The main focus was on changes in blood sugar…
Sponsor: Aalborg University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental diabetes drug AP026 tested in early trial – but study halted
Disease control TerminatedThis early-stage trial tested a new drug called AP026, a fusion protein that targets two pathways (GLP-1 and FGF21) to potentially treat type 2 diabetes. The study planned to enroll 74 healthy adults but was terminated early after only 14 participants. The main goal was to check …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pfizer's new cancer drug combo tested in tiny early trial
Disease control TerminatedThis early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Kidney-Liver drug trial halted early – what happened?
Disease control TerminatedThis small Phase 2 study tested two doses of vonafexor, an oral drug, in 10 people with mild-to-moderate chronic kidney disease and suspected MASH (a type of fatty liver disease). The goal was to see if vonafexor could improve kidney function. However, the trial was terminated ea…
Phase: PHASE2 • Sponsor: Enyo Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising cancer combo trial halted after just 7 patients
Disease control TerminatedThis early-phase trial tested a three-drug combination (ivosidenib, nivolumab, and ipilimumab) in 7 people with advanced bile duct cancer that has a specific IDH1 mutation. The goal was to check safety and find the right dose, but the study was stopped early by the sponsor before…
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New cancer drug AUR109 tested in three tumor types – trial halted early
Disease control TerminatedThis phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Experimental combo shot for pancreatic cancer stalls after just 2 patients
Disease control TerminatedThis very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 partici…
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control TerminatedThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase: PHASE1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental cancer drug TNG908 tested in patients with rare gene deletion
Disease control TerminatedThis study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have lost a gene called MTAP. The goal was to see if the drug is safe and can shrink tumors. The study was planned for up to 192 participants but was terminated early, so results a…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental lymphoma drug IPH6501 tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …
Phase: PHASE1, PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Surgery for spread pancreatic cancer? small trial halted early
Disease control TerminatedThis study tested whether surgically removing both the main pancreatic tumor and any limited spread to the liver or lungs could help people with pancreatic cancer live longer. Only 5 people enrolled before the trial was stopped early. Participants first received chemotherapy, the…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can cutting carbs and a diabetes drug help kidneys?
Disease control TerminatedThis small pilot study tested whether a low-carb diet (50-100 grams of carbs per day) combined with the diabetes drug dapagliflozin could improve blood sugar control in people with chronic kidney disease and prediabetes or type 2 diabetes. Four participants were split into two gr…
Phase: NA • Sponsor: Department of Nephrology Clinic Ottakring Vienna • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cancer drug GEN1047 tested in humans – study halted early
Disease control TerminatedThis study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail shows promise in tough lung cancers
Disease control TerminatedThis study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo tackles pancreatic cancer resistance – but study halted early
Disease control TerminatedThis study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug for cholesterol and fatty liver fails to advance
Disease control TerminatedThis early-stage trial tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and non-alcoholic fatty liver disease (NAFLD). The main goal was to check safety and how the body processes the drug. The study was terminated, meaning it stopped early, so it…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New antibody drug tested in patients with advanced stomach and gut cancers
Disease control TerminatedThis early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cancer combo trial ends before it begins: only one patient enrolled
Disease control TerminatedThis early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
BioNTech's RNA cancer therapy trial halted early
Disease control TerminatedThis study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail tested for ovarian cancer maintenance
Disease control TerminatedThis study looked at whether adding a third drug (fluzoparib) to a two-drug combination (apatinib and letrozole) could help control recurrent ovarian cancer longer. It included people with a specific type of ovarian cancer that had come back but still responded to platinum chemot…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Hepatitis b drug combo tested in phase 3 trial – but study stopped early
Disease control TerminatedThis study tested two antiviral drugs, clevudine and tenofovir, alone or together, in 150 adults with chronic hepatitis B who had not been treated before. The goal was to see which approach worked best at controlling the virus after 96 weeks of treatment and 24 weeks of follow-up…
Phase: PHASE3 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental cancer drug CPO-100 trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New vitamin d pill aims to tame parathyroid glands in dialysis patients
Disease control TerminatedThis phase 2 study tested a weekly extended-release capsule of calcifediol (CTAP101) in 44 adults with chronic kidney disease on hemodialysis who also had vitamin D insufficiency and secondary hyperparathyroidism. The goal was to see if the drug could raise vitamin D levels and l…
Phase: PHASE2 • Sponsor: OPKO Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Chemo cocktail aimed at zapping pancreatic cysts
Disease control TerminatedThis study tested whether injecting chemotherapy drugs directly into pancreatic cysts could shrink or eliminate them. It involved 75 adults with cysts between 2-5 cm. The approach used an endoscope to guide the injection, comparing two different pre-treatment rinses. The trial wa…
Phase: PHASE3 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Liver cancer trial tests new chemo combo without embolization
Disease control TerminatedThis phase 2 trial tested a liver-directed chemotherapy using idarubicin mixed with lipiodol (a fatty contrast agent) injected directly into the liver artery. The goal was to see if this could control non-spreading liver cancer in 44 patients with cirrhosis. The study was termina…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental IDH drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug, HMPL-306, in 42 adults with advanced solid tumors that have an IDH mutation. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited and no cure is expected.
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control TerminatedThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase: PHASE2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo targets deadly thyroid cancer
Disease control TerminatedThis phase 2 trial tested whether the immunotherapy drug pembrolizumab, given after radiation therapy, could help control anaplastic thyroid cancer that is still in the neck. Only 6 patients were enrolled before the study was stopped early. The goal was to see how long patients l…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Radioactive microparticles injected into pancreatic tumors: a new hope?
Disease control TerminatedThis study aimed to see if injecting radioactive particles (OncoSil) directly into pancreatic tumors during an endoscopic ultrasound, combined with chemotherapy, could safely shrink tumors and improve survival. It was designed for people with advanced pancreatic cancer that could…
Phase: PHASE2, PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immune cell therapy tested for tough childhood cancers
Disease control TerminatedThis early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental KRAS blocker tested in advanced cancers – trial halted early
Disease control TerminatedThis early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Plant-Based diet shows promise for diabetes remission in new study
Disease control TerminatedThis study looked at whether a plant-based diet and lifestyle changes could help people with type 2 diabetes, prediabetes, or obesity improve their health. Researchers aimed for diabetes remission (normal blood sugar without medication for at least 3 months) or significant weight…
Phase: NA • Sponsor: National Council of Scientific and Technical Research, Argentina • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Cancer drug olaparib tested for rare pancreatic tumor
Disease control TerminatedThis phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare pancreatic cancer. Participants took olaparib pills twice daily for up to 2 years. The study was terminated early after enrolling only 5 people, so it is not kn…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Immunotherapy combo tested for tough thyroid cancers
Disease control TerminatedThis phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full…
Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Liver cancer drug combo put to the test – but trial stops early
Disease control TerminatedThis phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people bu…
Phase: PHASE3 • Sponsor: Translational Research in Oncology • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental virus therapy VAXINIA tested in advanced cancer patients
Disease control TerminatedThis early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Liver cancer study halted after just 2 patients
Disease control TerminatedThis study aimed to see if adding electromagnetic fields to the drug regorafenib could help people with advanced liver cancer live longer without their cancer growing. It was designed for patients who had already tried other treatments. However, the study was stopped early after …
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cancer drug DCC-3084 tested in early trial
Disease control TerminatedThis early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug (BMS-986218) plus nivolumab and targeted radiation in people with advanced solid tumors that had spread. The goal was to see if this combination could help the immune system fight cancer better. Only 13 people took part before the study was stopped ea…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental kidney cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental drug entinostat studied for rare abdominal cancer, trial halted early
Disease control TerminatedThis study tested a drug called entinostat in people with advanced abdominal neuroendocrine tumors that had come back or stopped responding to other treatments. Only 5 people enrolled before the trial was stopped early. The goal was to see if the drug could shrink tumors or slow …
Phase: PHASE2 • Sponsor: Antonio Fojo • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a common diabetes drug shield transplanted kidneys?
Disease control TerminatedThis study tested the drug empagliflozin (a diabetes medicine) in 20 people who had a kidney transplant, some with type 2 diabetes and some without. The goal was to see if the drug could help protect their heart and kidney function. The trial was stopped early, so the findings ar…
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Probiotic study for diabetes and COPD halted early
Disease control TerminatedThis study looked at whether taking probiotics alongside regular treatment could help lower blood sugar and improve lung function in people with both type 2 diabetes and chronic obstructive pulmonary disease (COPD). The trial planned to enroll 30 adults aged 50-85, but it was ter…
Phase: NA • Sponsor: Glac Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope: drug may shield brain from CAR T-Cell therapy side effects
Disease control TerminatedThis study tested whether the drug anakinra could prevent severe brain inflammation (called ICANS) that sometimes happens after CAR T-cell therapy for certain types of lymphoma. The trial involved 23 adults whose lymphoma had returned or not responded to prior treatments. Researc…
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a viagra drug help fight liver cancer? new trial tests unlikely combo
Disease control TerminatedThis phase 2 trial tested a combination of three drugs—nivolumab (an immunotherapy), tadalafil (commonly used for erectile dysfunction), and vancomycin (an antibiotic)—in adults with liver cancer or liver metastases from colorectal or pancreatic cancers that had not responded to …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cancer drug shows early promise, but trial cut short
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New vaccine aims to tame hepatitis b in patients on antivirals
Disease control TerminatedThis study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could safely lower hepatitis B surface antigen levels and possibly allow…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental diabetes drug trial halted early – what happened?
Disease control TerminatedThis study tested a new drug called CK-0045 in 90 adults with type 2 diabetes and overweight or obesity. Participants received weekly injections of CK-0045 or a placebo for 16 weeks to see if it improved blood sugar after meals and reduced body weight. The trial was terminated ea…
Phase: PHASE2 • Sponsor: Cytoki Pharma • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New tech approach aims to prevent repeat hospital stays for diabetes patients
Disease control TerminatedThis study tested whether a team-based approach using continuous glucose monitors could help adults with type 1 diabetes better control their blood sugar and avoid another hospital stay after a diabetic ketoacidosis (DKA) episode. Only 2 people enrolled before the study was stopp…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Liver surgery combo fails to show clear survival edge in advanced colorectal cancer
Disease control TerminatedThis study looked at whether removing liver tumors with surgery, along with chemotherapy, helps people with colorectal cancer that has spread to the liver and lungs live longer compared to chemotherapy alone. The trial was stopped early after enrolling only 29 participants. The r…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Liver cancer drug trial halted early – what we know so far
Disease control TerminatedThis study tested a drug called cadonilimab in people with liver cancer who had surgery to remove their tumor but were at high risk of the cancer returning. The goal was to see if the drug could help keep the cancer away. The trial was stopped early, so the full results are not y…
Phase: PHASE2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control TerminatedThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Pancreatic cancer drug trial halted after just two patients
Disease control TerminatedThis phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a new drug help preserve insulin production in type 1 diabetes?
Disease control TerminatedThis early-stage trial tested four different doses of siplizumab in 8 people aged 8–45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that changes certain immune cell patterns linked to better insulin production. Participants r…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising cancer combo trial halted after just 2 patients
Disease control TerminatedThis early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…
Phase: PHASE1, PHASE2 • Sponsor: Ariceum Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on Hard-to-Treat gut cancers
Disease control TerminatedThis early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel …
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Diabetes drug liraglutide may fight fatty liver, but trial halted early
Disease control TerminatedThis study looked at whether liraglutide, a diabetes drug, can reduce liver fat and improve cholesterol in people with type 2 diabetes. It involved 127 patients who took liraglutide for 6 months, with liver fat measured by MRI. However, the trial was terminated early, so the full…
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental drug shows promise for Hard-to-Treat prostate cancer
Disease control TerminatedThis phase 2 study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The goal was to see if the drug could slow the cancer and to study bone and blood markers. The trial was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental drug BI 765883 tested in pancreatic cancer – early trial ends
Disease control TerminatedThis early study tested an experimental drug called BI 765883, alone or with chemotherapy, in 8 adults with advanced pancreatic cancer. The goal was to find a safe dose and see if it helps shrink tumors. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Lung cancer drug trial halted early: what toripalimab Couldn't prove
Disease control TerminatedThis phase II trial tested whether the immunotherapy drug toripalimab could help patients with limited-stage small cell lung cancer stay cancer-free longer after standard chemoradiotherapy. The study planned to enroll 170 adults aged 18-75 who had not progressed after treatment. …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Ovarian cancer drug combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on pancreatic cancer in early trial
Disease control TerminatedThis early-phase study tested a treatment called huCART-meso cells, which are a patient's own immune cells modified to recognize and attack pancreatic cancer cells. The trial included 54 people with advanced pancreatic cancer that could not be removed by surgery. The main goal wa…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Phase: PHASE1, PHASE2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cancer drug tested in people with advanced tumors
Disease control TerminatedThis early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Lung cancer trial adding radiation to immunotherapy halted early
Disease control TerminatedThis study looked at whether adding radiation to the chest could improve survival for people with extensive-stage small-cell lung cancer who were already receiving chemotherapy and immunotherapy. The trial planned to enroll 239 participants but was terminated early. The main goal…
Phase: PHASE3 • Sponsor: Norwegian University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Old arthritis drug tested against rare tumor syndrome – but trial stalls
Disease control TerminatedThis study tested leflunomide, a drug used for rheumatoid arthritis, in 3 adults with MEN1 syndrome—a genetic condition that raises the risk of multiple tumors. The goal was to see if 6 months of daily leflunomide could shrink or stabilize tumors. However, the trial was terminate…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Bile duct cancer trial halted after just one patient
Disease control TerminatedThis phase II trial tested a combination of chemotherapy infused directly into the liver (HAIC) plus two immunotherapy drugs (atezolizumab and bevacizumab) given before and after surgery for high-risk bile duct cancer. The goal was to see if this approach could shrink tumors and …
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Cancer drug combo trial for kids halted early
Disease control TerminatedThis early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumo…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hepatitis b drug trial halted after early safety check
Disease control TerminatedThis early-stage study tested a new medicine called RO7565020 in healthy volunteers and people with chronic hepatitis B. The goal was to see if the drug is safe and how the body processes it. The trial was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental drug shows promise for recurrent gynecologic cancers
Disease control TerminatedThis study tested a drug called sacituzumab govitecan in people with ovarian, endometrial, or cervical cancer that returned after at least two rounds of standard treatment. The goal was to see if the drug could shrink or eliminate tumors. The study was terminated early with only …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Promising cancer drug trial halted after just one patient
Disease control TerminatedThis study aimed to see if giving Lutathera (a radioactive drug) after surgery to remove liver metastases from neuroendocrine tumors could help keep the cancer from coming back. It planned to compare Lutathera plus best supportive care against best supportive care alone in about …
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental liver drug shows early promise but trial cut short
Disease control TerminatedThis early study tested a drug called VS-01 in 15 adults with acute-on-chronic liver failure (a sudden worsening of liver function) and fluid buildup in the belly. Participants received either VS-01 plus standard care or standard care alone. The trial was terminated early, so we …
Phase: PHASE2 • Sponsor: Genfit • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, …
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis Phase 2 trial tested an experimental drug called ARC-520 in 58 people with chronic hepatitis B who were already taking standard antivirals. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels, a marker of the virus. The study was terminated …
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis study tested a new drug called ARC-520 in 79 people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it combined with standard treatments like entecavir or tenofovir. The goal was to see if ARC-520 could lower hepatitis B surface antigen l…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Hepatitis b drug trial halted early after safety check
Disease control TerminatedThis early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The main goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug combo shows promise but study halted early
Disease control TerminatedThis study tested an experimental drug called ARC-520 given alongside standard hepatitis B medications (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks to see if it could safely lower hepatitis B virus levels. …
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis study tested whether a new drug called ARC-520, given with the standard medicine entecavir, could lower hepatitis B virus levels in people with chronic hepatitis B. About 58 adults with different stages of infection received either ARC-520 or a placebo. The study was stopped…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called ARC-520 in 32 adults with chronic hepatitis B who were already taking antiviral medications (entecavir or tenofovir). The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial wa…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Liver drug trial halted after just 3 patients
Disease control TerminatedThis study tested a drug called VS-01 for people with severe confusion caused by liver disease (overt hepatic encephalopathy). The trial planned to enroll many participants but was stopped early after only 3 people joined. Researchers wanted to see if VS-01 could help patients re…
Phase: PHASE2 • Sponsor: Genfit • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control TerminatedThis study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was termi…
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immune cells supercharged to fight ovarian cancer
Disease control TerminatedThis early-stage study tested a new way to treat ovarian, fallopian tube, or primary peritoneal cancer that had returned or stopped responding to standard treatments. Researchers took a type of white blood cell (monocytes) from each participant, stimulated them with two immune-bo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising combo for Hard-to-Treat cancers hits early snag
Disease control TerminatedThis study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study w…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Does longer glucose monitoring help diabetes control? small study halted early
Disease control TerminatedThis study aimed to see if using a professional continuous glucose monitor (CGM) for 6 months, instead of 3 months, helps people with poorly controlled type 2 diabetes (who don't use insulin) spend more time with healthy blood sugar levels. Only 12 participants were enrolled befo…
Phase: NA • Sponsor: East Tennessee State University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising cancer drug trial halted early: what happened?
Disease control TerminatedThis study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific gene mutations (BRCA or HRD) and had stopped responding to first treatment. The goal was to see if Promitil could control tumor growth safely. The trial was terminated early,…
Phase: PHASE2 • Sponsor: Lipomedix Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Vitamin-Like supplement tested for diabetic nerve pain – but trial stopped early
Disease control TerminatedThis early-phase trial tested whether nicotinamide riboside (a form of vitamin B3 sold as Niagen) could help repair nerve damage in people with type 2 diabetes or prediabetes. Only 10 participants were enrolled before the study was terminated. The main goal was to measure changes…
Phase: PHASE1, PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control TerminatedThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Proton beam therapy tested for liver cancer – early results show promise and risks
Disease control TerminatedThis phase II trial tested a precise type of radiation called proton beam therapy in 9 people with liver cancer. The goal was to see if it could control the cancer while limiting damage to the liver. The study was stopped early, so the findings are limited, but early data suggest…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental combo shows promise for tough bile duct cancer
Disease control TerminatedThis study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose …
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immunotherapy combo before liver surgery shows promise for advanced colorectal cancer
Disease control TerminatedThis study tested two drugs, pembrolizumab and vactosertib, given before and after surgery to remove liver tumors in people with colorectal cancer that had spread to the liver. The goal was to see if these drugs could shrink the liver tumors before surgery and lower the chance of…
Phase: PHASE2 • Sponsor: Chloe Atreya, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for kids with rare hormone disorder: drug may cut steroid doses
Disease control TerminatedThis study tested an experimental drug called tildacerfont in 67 children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The goal was to see if adding this once-daily pill to standard steroid treatment could improve d…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental radioactive therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tested a radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, gastroesophageal, or brain cancer. The drug seeks out and attaches to specific proteins on cancer cells to deliver radiation directly. The main goals were to check safety, fi…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can a home device keep cirrhosis patients out of the hospital?
Disease control TerminatedThis study tested whether a home monitoring kit (measuring blood pressure, weight, and pulse) plus care coordination could reduce hospital readmissions in people with cirrhosis. It enrolled 120 patients with serious complications like fluid buildup or confusion. The trial was ter…
Phase: EARLY_PHASE1 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental bile duct cancer drug tested in tiny trial – already halted
Disease control TerminatedThis early-stage trial tested a new drug called NXP800 in 7 people with advanced bile duct cancer that had spread or stopped responding to treatment. The goal was to find a safe dose and see if the drug could shrink tumors by blocking a protein linked to cancer growth. However, t…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Digital diabetes coach put to the test – but trial ends early
Disease control TerminatedThis study tested a digital system called 'Live well with type 2 diabetes' to help people manage their condition. It compared the digital program to usual care for 138 adults recently diagnosed with type 2 diabetes. The main goal was to see if it improved blood sugar levels. Howe…
Phase: NA • Sponsor: Region Jönköping County • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Liver cancer combo trial halted early – only 18 patients enrolled
Disease control TerminatedThis study tested whether adding a stronger chemotherapy infusion (HAIC-TACE) to the targeted drug donafenib works better than standard treatment for people with intermediate-stage liver cancer that cannot be removed by surgery. The trial was stopped early and only included 18 pa…
Phase: PHASE2, PHASE3 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug hope for fatty liver in PCOS women?
Disease control TerminatedThis study tested a drug called saroglitazar in women with polycystic ovary syndrome (PCOS) who also have nonalcoholic fatty liver disease (NAFLD). The goal was to see if the drug could safely reduce liver fat over 24 weeks compared to a placebo. The trial was planned for 60 wome…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental drug aims to save Insulin-Making cells in newly diagnosed type 1 diabetes
Disease control TerminatedThis Phase 2 trial tested an oral drug called ladarixin in 141 people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if ladarixin could preserve the body's ability to produce insulin by protecting beta cells. The study was terminated early, so while it ma…
Phase: PHASE2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Bile duct cancer combo trial halted early
Disease control TerminatedThis study tested a new drug combination (GEN-001 plus pembrolizumab) in 10 adults with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so final …
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Measles virus takes on ovarian cancer in early trial
Disease control TerminatedThis phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental combo for tough pancreatic cancer shows early promise
Disease control TerminatedThis early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was st…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
HepTcell hepatitis b vaccine trial ends early: what it means
Disease control TerminatedThis study tested a treatment called HepTcell, which is like a vaccine that trains the immune system to fight the hepatitis B virus. It was for people with inactive chronic hepatitis B who had not received treatment before. The goal was to see if it could lower virus levels or cl…
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Cancer combo trial halted early – what went wrong?
Disease control TerminatedThis phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Ovarian cancer drug trial halted early: what happened?
Disease control TerminatedThis study aimed to see if the drug niraparib works better than standard chemotherapy before surgery for people with a specific type of advanced ovarian cancer (stage III or IV with HRd). The trial was planned for 36 participants but was stopped early. Researchers wanted to measu…
Phase: PHASE2 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cancer drug BLU-222 tested in early trial – but study stopped early
Disease control TerminatedThis early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a new drug combo prevent liver failure after tylenol overdose?
Disease control TerminatedThis study tested whether adding fomepizole to the standard treatment (N-acetylcysteine) could better protect the liver in people who took too much acetaminophen (Tylenol). The trial included 29 adults and children aged 10 and older who were at high risk for liver injury. The goa…
Phase: PHASE2 • Sponsor: Richard Dart, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental drug combo for advanced liver cancer tested, but trial stopped early
Disease control TerminatedThis early-stage study tested a new drug combination (TQB2223 plus penpulimab) in 22 adults with advanced liver cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Shorter infusion may be just as good for preventing repeat variceal bleeding
Disease control TerminatedThis study looked at whether giving the drug octreotide for 24 hours instead of the usual 72 hours could prevent early rebleeding from esophageal varices in people with cirrhosis. The trial included 34 adults with active bleeding from varices who underwent endoscopic banding. The…
Phase: PHASE4 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Cancer-Fighting virus injected directly into tumors shows promise in early trial
Disease control TerminatedThis early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Early scope procedure fails to show clear benefit in severe pancreatitis trial
Disease control TerminatedThis study tested whether doing an early endoscopic ultrasound and removing any gallstones from the bile duct could help people with severe pancreatitis caused by gallstones. The trial planned to enroll many patients but was stopped early after only 27 participants. The main goal…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo therapy aimed at Hard-to-Treat liver disease
Disease control TerminatedThis study tested whether combining two drugs, obeticholic acid and bezafibrate, could improve liver health in people with primary biliary cholangitis (PBC) who did not respond well to or could not take the standard medicine. The trial enrolled 75 adults and measured changes in a…
Phase: PHASE2 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control TerminatedThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental pancreatic cancer combo trial halted early
Disease control TerminatedThis early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination c…
Phase: PHASE1 • Sponsor: Colin D. Weekes, M.D., PhD • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Pancreatic cancer drug trial halted after safety issues
Disease control TerminatedThis trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeare…
Phase: PHASE1, PHASE2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
AI-Powered diabetes coach could replace some doctor visits
Disease control TerminatedThis study tested a software called DreaMed Advisor Pro that automatically analyzes blood sugar and insulin pump data to suggest insulin dose adjustments. About 100 people with type 1 diabetes (ages 6-30) were split into two groups: one received recommendations directly from the …
Phase: NA • Sponsor: Rabin Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill shows promise against tough breast and ovarian cancers
Disease control TerminatedThis study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future …
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental cancer drug study halted early
Disease control TerminatedThis study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…
Phase: PHASE1, PHASE2 • Sponsor: Shasqi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental drug combo for pancreatic cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase trial tested a drug called CPI-613 (devimistat) combined with chemotherapy and radiation for people with pancreatic cancer that cannot be surgically removed. The goal was to find the safest dose. Only 8 people took part before the study was stopped. While the app…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer-Fighting super cells tested in solid tumors – study halted early
Disease control TerminatedThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…
Phase: PHASE1, PHASE2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Prostate cancer drug trialed to reduce steroids in kids with rare hormone disorder
Disease control TerminatedThis early-phase study tested a drug called abiraterone acetate (normally used for prostate cancer) in 4 children with congenital adrenal hyperplasia (CAH). The goal was to see if it could lower high male hormone levels and reduce the need for strong steroid medications that can …
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental hepatitis b drug trial halted early
Disease control TerminatedThis study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels. Only 4 people enrolled before the study was stop…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising cancer drug falls short in rare tumor trial
Disease control TerminatedThis study tested the drug TAS-102 (also known as Lonsurf) in 14 people with a rare and aggressive type of neuroendocrine cancer that started outside the lungs. The goal was to see if the drug could shrink tumors or improve survival. The trial was stopped early, so results are li…
Phase: PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Lung cancer maintenance combo trial stopped early
Disease control TerminatedThis study tested whether adding the drug vorolanib to standard maintenance therapy with atezolizumab could help people with extensive-stage small cell lung cancer stay cancer-free longer after initial chemotherapy. Only 11 participants were enrolled before the study was terminat…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cancer drug LY3405105 fails to advance in early trial
Disease control TerminatedThis early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control TerminatedThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase: PHASE1, PHASE2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Liver drug trial for kids with biliary atresia ends early
Disease control TerminatedThis study tested the drug obeticholic acid in children with biliary atresia who had already undergone Kasai surgery. The goal was to see if the drug could improve outcomes like avoiding liver transplant or death. The trial was terminated early and enrolled only 28 participants, …
Phase: PHASE2, PHASE3 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Pancreatic cancer combo trial halted after just one patient
Disease control TerminatedThis study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) after surgery could help prevent pancreatic cancer from coming back. It was designed for people whose tumors were fully removed. However, the trial was stopped early after enroll…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug INCB062079 tested in early trial
Disease control TerminatedThis early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental combo for skin cancer shows early promise but study halted
Disease control TerminatedThis study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded …
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Liver cancer drug combo study halted early
Disease control TerminatedThis study tested a new way to deliver an immune-boosting drug (SD-101) directly into the liver along with standard immunotherapy for people with advanced liver cancer. It included 23 adults whose cancer had not responded to prior treatment. The goal was to find a safe dose and s…
Phase: PHASE1, PHASE2 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug ZW171 tested in 32 patients, but study stopped early
Disease control TerminatedThis early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New dual-targeting CAR t therapy tested for hard-to-treat lymphoma
Disease control TerminatedThis early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize a…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Fatty liver drug trial halted early: what we know
Disease control TerminatedThis early-stage study tested an experimental drug called FT-4101 in 14 overweight or obese adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat. The study was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug ASP2074 trial halted early
Disease control TerminatedThis early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental liver cancer drug shows promise in early trial
Disease control TerminatedThis phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 13 people with advanced liver cancer that had not responded to prior treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: American Regent, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Liver cancer combo trial halted early – what it means
Disease control TerminatedThis phase II trial tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy drug nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. Only 13 participants were enrolled before the study was terminated. The goal was …
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising pancreatic cancer combo trial halted early
Disease control TerminatedThis study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental cancer drug AMG 199 tested in patients with stomach, colon, and pancreatic tumors
Disease control TerminatedThis early-phase study tested an experimental drug called AMG 199 in adults with advanced stomach, gastroesophageal junction, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goals were to check safety and find the best dose. The study was stopped …
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Heart drug digoxin tested for alcoholic hepatitis – early trial halted
Disease control TerminatedThis small, early-phase study tested whether the heart medication digoxin could reduce inflammation in people with severe alcohol-associated hepatitis. 23 participants were randomly assigned to receive intravenous digoxin or no digoxin for up to 28 days. The trial was terminated …
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
PCOS drug trial halted early: did tildacerfont lower hormones?
Disease control TerminatedThis study tested a drug called tildacerfont in 27 women with polycystic ovary syndrome (PCOS) who had high levels of adrenal androgens (hormones). The goal was to see if the drug could safely lower these hormones. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Early cancer drug trial halted after just 3 patients
Disease control TerminatedThis early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Liver cancer drug combo shows promise but study halted early
Disease control TerminatedThis study tested whether two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors in people with advanced liver cancer that had already been treated with another drug combination. The trial enrolled 15 adults whose cancer had spread or could not be removed by surge…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug aims to cut steroid use in rare hormone disorder
Disease control TerminatedThis study tested a daily tablet called Tildacerfont in 100 adults with classic congenital adrenal hyperplasia, a condition where the body can't make certain hormones properly. The goal was to see if the drug could safely reduce the high doses of steroids patients need to take. T…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental drug targets Hard-to-Treat cancers in new trial
Disease control TerminatedThis phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental cancer combo trial halted early – what we know
Disease control TerminatedThis early-phase trial tested an experimental drug called WJ05129, taken as a tablet, together with the chemotherapy drug paclitaxel in people with advanced solid tumors that had spread. The study aimed to find safe doses and check for side effects. Only 26 people were enrolled, …
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Junjing BioSciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control TerminatedThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug study halted early: what we know
Disease control TerminatedThis study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Heart drug for diabetics shows promise but trial ends early
Disease control TerminatedThis study tested whether pemafibrate, a drug that lowers triglycerides, could reduce heart attacks, strokes, and heart-related deaths in over 10,000 people with type 2 diabetes and high triglycerides. Participants took either pemafibrate or a placebo twice daily. The trial was t…
Phase: PHASE3 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Radiation after failed CAR t: tiny study halted early
Disease control TerminatedThis pilot study looked at whether radiation therapy could help people with lymphoma that did not respond to CAR T cell therapy. Only 3 participants were enrolled before the study was terminated. The main goal was to check safety and side effects of adding radiation shortly after…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Cancer combo trial halted early: what we know
Disease control TerminatedThis phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…
Phase: PHASE2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental ovarian cancer drug combo studied in early trial
Disease control TerminatedThis early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for tough ovarian cancer? trial tests smart drug vs chemo
Disease control TerminatedThis study tested a new drug called luveltamab tazevibulin (STRO-002) against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated …
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Radioactive beads aim to shrink untreatable liver tumors
Disease control TerminatedThis early trial tested the safety and effectiveness of radioactive beads (Holmium-166 microspheres) in 4 adults with liver cancer that could not be removed by surgery or transplant. Participants first received a small scout dose to check for proper placement, then a personalized…
Phase: NA • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 19:18 UTC
-
Experimental cancer pill targets Hard-to-Treat gene mutations
Disease control TerminatedThis early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC
-
Study on adding albumin to diuretics for cirrhosis fluid retention halted early
Disease control TerminatedThis study aimed to see if adding albumin to the diuretic furosemide helps people with cirrhosis lose excess fluid better than furosemide alone. The trial planned to enroll 21 adults with cirrhosis and fluid buildup. However, it was terminated early due to funding problems, and n…
Phase: PHASE4 • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Jun 26, 2026 18:16 UTC
-
Pfizer's new cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
New cancer drug LB4330 tested in early trial
Disease control TerminatedThis early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Jun 26, 2026 16:51 UTC
-
Experimental immune cell therapy for liver cancer hits early roadblock
Disease control TerminatedThis early-stage trial tested a new type of immune cell therapy (ET140203 T cells) in 8 adults with advanced liver cancer that had not responded to other treatments. The therapy was designed to target a protein called AFP found on cancer cells. The study was terminated early, so …
Phase: PHASE1 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:13 UTC
-
Insulin showdown: toujeo vs tresiba for diabetics with kidney disease
Disease control TerminatedThis study compared two long-acting insulins, Toujeo and Tresiba, in people with type 2 diabetes who also have kidney problems and had never used insulin before. The goal was to see which one controls blood sugar better and causes fewer low blood sugar events. The trial was stopp…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:43 UTC
-
CAR T-Cell trial for rare lymphoma halted after just one patient
Disease control TerminatedThis study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to initial treatment. The goal was to see if it could shrink tumors and improve outcomes. However, the trial was terminated e…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC
-
Experimental combo for tough lung cancer shows early promise, but study halted
Disease control TerminatedThis early-phase trial tested an experimental antibody called hSTC810 combined with the chemotherapy drug paclitaxel in 10 adults with relapsed or refractory extensive-stage small cell lung cancer. The goal was to see if the combination is safe and helps shrink tumors or slow the…
Phase: PHASE1, PHASE2 • Sponsor: STCube, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC
-
New drug combo aims to lower liver vein pressure in cirrhosis patients
Disease control TerminatedThis study tested whether the drug Avenciguat, taken alone or with empagliflozin, can lower high blood pressure in the portal vein (the main vessel to the liver) in people with cirrhosis. About 90 adults with cirrhosis from hepatitis or fatty liver disease were enrolled. The tria…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC
-
Hepatitis b cure hope fades as early trial ends
Disease control TerminatedThis small phase 2 trial tested whether giving hepatitis B antibodies (HBIG) could clear the hepatitis B surface antigen in people with chronic hepatitis B. Only 13 patients were enrolled before the study was terminated. The goal was to see if a 12-week course of injections could…
Phase: PHASE2 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jun 26, 2026 13:38 UTC
-
Experimental pill avenciguat targets liver blood pressure in cirrhosis – but trial halted early
Disease control TerminatedThis study tested a drug called Avenciguat in adults with liver cirrhosis and high blood pressure in the portal vein (the main vessel to the liver). Participants took either a low or high dose of Avenciguat or a placebo twice daily for 24 weeks. The goal was to see if the drug co…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 26, 2026 12:44 UTC
-
New drug combo tested for Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:43 UTC
-
New automated insulin system tested in tiny trial
Disease control TerminatedThis study tested a system that automatically adjusts insulin delivery using a continuous glucose monitor, a smartphone app, and an insulin pump. It aimed to see if the system could help adults with type 1 diabetes spend more time with their blood sugar in a healthy range. Only o…
Phase: NA • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 12:39 UTC
-
Fatty liver drug trial in HIV patients stalls after enrolling just 4 people
Disease control TerminatedThis study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaning…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
Pee test could replace pap smear for some women
Diagnosis TerminatedThis study tested whether offering a home urine test for human papillomavirus (HPV) could encourage more women to get screened for cervical cancer. The trial targeted women aged 30–65 in Brittany, France, who had not responded to an initial invitation for a Pap smear. Participant…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New scan spots hidden thyroid cancer better?
Diagnosis TerminatedThis study tested a new type of PET scan (called 68Ga-MY6349) that targets a protein called Trop-2 on cancer cells. It was used in 149 adults with thyroid cancer to see if it could find cancer that had come back or spread. The results were compared to the standard FDG-PET scan to…
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
New scan could sharpen ovarian cancer detection
Diagnosis TerminatedThis study tested whether a new radioactive tracer called FAPI-46, used with a PET/CT scan, can more accurately detect the spread of ovarian cancer compared to standard scans. Researchers planned to enroll 50 women with newly diagnosed ovarian cancer, but the study was terminated…
Phase: PHASE2 • Sponsor: Aalborg University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis TerminatedThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase: PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New ovarian imaging could cut unneeded surgeries by 23%
Diagnosis TerminatedThis study tested whether adding photoacoustic imaging to standard ultrasound can better tell if an ovary is cancerous or benign. Researchers aimed to reduce the number of women who have surgery to remove an ovary that turns out to be non-cancerous. The study enrolled 185 women s…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
Blood RNA may reveal hidden liver cancers
Diagnosis TerminatedThis study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Blood test may spot pancreatic cancer without needle biopsy
Diagnosis TerminatedThis study looked at whether a blood test that detects circulating tumor cells (CTCs) could diagnose pancreatic cancer. Researchers planned to compare the blood test results with standard tissue biopsies in 101 people with pancreatic tumors. The trial was terminated early, so the…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
GPS and glowing dye aim to make liver biopsies more accurate
Diagnosis TerminatedThis study tested a new method to improve liver biopsies for people with suspected liver cancer. It combined a GPS-like tracking system with a special dye (ICG) that makes cancer cells glow. Seven adults participated, and the goal was to see if this combination could help doctors…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
New Hand-Held imager aims to prevent accidental parathyroid damage in thyroid surgery
Diagnosis TerminatedThis early study tested a hand-held imaging device to help surgeons identify parathyroid glands during thyroid surgery. The parathyroid glands are small and hard to see, and if accidentally removed or damaged, can cause low calcium levels and other complications. The device uses …
Phase: PHASE1 • Sponsor: OPTOSURGICAL, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New imaging agent aims to spot Hard-to-Find cancers
Diagnosis TerminatedThis early-phase trial tested a radioactive imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors (glioblastoma, brain metastases from breast cancer, gastroesophageal cancer, or pancreatic cancer). The goal was to see if the agent could help detect these …
Phase: EARLY_PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
Smartwatch aims to replace finger pricks and cuffs
Diagnosis TerminatedThis Mayo Clinic study tested a special smartwatch that uses light sensors to measure blood glucose, blood pressure, and heart signals. The goal was to see if the watch could give accurate readings compared to standard methods like finger-stick tests and blood pressure cuffs. The…
Phase: NA • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
New ultrasound technique aims to spot cancer without radiation
Diagnosis TerminatedThis study tested a new 3D ultrasound technique called acoustic angiography to improve imaging of breast and thyroid tumors. Researchers planned to enroll 45 people, including healthy volunteers and patients scheduled for biopsy. The study was stopped early due to funding problem…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug aims to prevent bleeding veins in fatty liver disease
Prevention TerminatedThis study tested a drug called belapectin to see if it could prevent the formation of esophageal varices (enlarged veins in the esophagus) in people with NASH cirrhosis and signs of high blood pressure in the liver. The trial enrolled 357 adults and compared belapectin to a plac…
Phase: PHASE2, PHASE3 • Sponsor: Galectin Therapeutics Inc. • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Sugar-Free diet may shield hispanic kids from fatty liver
Prevention TerminatedThis study tested whether a low-sugar diet could prevent non-alcoholic fatty liver disease (NAFLD) in Hispanic children ages 6 to 9 who were at higher risk. Over two years, researchers compared kids who followed the diet with those who ate normally. The goal was to see if cutting…
Phase: NA • Sponsor: Emory University • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Porphyria prevention study halted early – little data to go on
Prevention TerminatedThis small phase 2 trial tested whether the drug Panhematin could prevent acute attacks in people with certain types of porphyria. Only 13 participants were enrolled before the study was terminated early. Researchers tracked attacks and serious side effects, but the limited data …
Phase: PHASE2 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Yoghurt study aimed to curb diabetes risk, but ended early
Prevention TerminatedThis study tested whether eating yoghurt daily for 24 weeks could improve blood sugar control in adults with prediabetes (high risk for type 2 diabetes). Only 8 people enrolled, and the study was stopped early, so no firm conclusions can be drawn. The goal was to see if a simple …
Phase: NA • Sponsor: Danone Global Research & Innovation Center • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief TerminatedThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Ear device aims to cut opioid use after liver transplant
Symptom relief TerminatedThis study tested a small device worn on the ear that uses mild electrical pulses to help control pain after a liver transplant. The goal was to see if it could reduce the need for strong painkillers like opioids. The study was stopped early and included 27 adults waiting for a l…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Diabetes education tailored for hispanic men shows promise in small study
Symptom relief TerminatedThis study tested whether a five-week culturally tailored diabetes education program could help Hispanic men aged 18-64 with type 2 diabetes improve their self-management behaviors like healthy eating, physical activity, and medication use. The program was designed specifically f…
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a simple ear massage help cancer patients eat better?
Symptom relief TerminatedThis small pilot study tested whether applying acupressure to the ear could help improve appetite and prevent weight loss in people with advanced stomach, esophagus, or pancreatic cancer. The approach uses small adhesive pellets placed on specific ear spots to stimulate the nervo…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief TerminatedThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase: PHASE2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Herbal brew for early puberty? trial ends early
Symptom relief TerminatedThis study tested a traditional Chinese herbal formula called Qingwei Huazhuo Decoction in 94 girls with mild early puberty (breast development starting too soon). The goal was to see if the herbs could slow breast growth and bone age. However, the trial was terminated early, so …
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Ear zapper aims to replace opioids for vomiting syndrome
Symptom relief TerminatedThis study tested a small device that stimulates nerves in the ear to help people with cyclic vomiting syndrome feel less pain, nausea, and vomiting. The goal was to see if it could reduce the need for strong painkillers like opioids. Only 4 people took part before the study was …
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Can a short daily workout help hospitalized diabetes patients?
Symptom relief TerminatedThis study tested whether hospitalized adults with type 2 diabetes or prediabetes could safely do 30 minutes of resistance training each day. The goal was to see if this exercise routine is feasible and if it helps control blood sugar and prevent muscle loss during a hospital sta…
Phase: PHASE1 • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New study tests safer pain relief for kids with pancreatitis
Symptom relief TerminatedThis study tested whether using less opioids for initial pain relief in children with acute pancreatitis is as effective and safer than the usual opioid-first approach. It involved 23 children at Boston Children's Hospital. The goal was to gather data for a larger future trial.
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Diabetes drug may ease thyroid treatment side effects
Symptom relief TerminatedThis small pilot study tested whether metformin, a common diabetes drug, could reduce side effects like dry mouth and taste changes from radioactive iodine treatment in people with thyroid cancer. Only 13 people took part, and the study was stopped early. The goal was to see if m…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Mood drug trial for pancreatic cancer patients halted early
Symptom relief TerminatedThis study tested whether the antidepressant escitalopram could reduce depression in people with localized pancreatic or related cancers who were receiving chemotherapy before surgery. Only 4 participants enrolled before the trial was stopped. The goal was to measure changes in d…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Radiation plus chemo for pancreatic cancer pain: trial ends early
Symptom relief TerminatedThis phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the …
Phase: PHASE2 • Sponsor: Ludwig-Maximilians - University of Munich • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New drug aimed at easing diabetic nerve pain hits roadblock
Symptom relief TerminatedThis study tested an experimental drug called GSK3858279 in 147 adults with chronic nerve pain from diabetes. The goal was to see if it could reduce pain better than a placebo. However, the trial was terminated early, so we have less information than planned.
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Weight-Loss drug trial for pancreatic cancer halted early
Symptom relief TerminatedThis study tested a drug called anamorelin to see if it could help prevent weight loss and improve appetite in people with advanced pancreatic cancer who were starting chemotherapy. The trial planned to include about 100 participants but was stopped early after only 4 people enro…
Phase: PHASE2 • Sponsor: Lahey Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Can a smartphone app ease cancer treatment side effects?
Symptom relief TerminatedThis study tested whether a digital health app (Roche DPM Module) helps cancer patients manage symptoms and reduce healthcare visits while on systemic treatment. About 49 participants used the app alongside standard care. The trial was terminated early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
How does a blood disorder drug perform in everyday practice?
Knowledge-focused TerminatedThis study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goa…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Diabetes and antibiotics: a risky mix for the heart?
Knowledge-focused TerminatedThis study looks at how high blood sugar combined with a medication called moxifloxacin (an antibiotic known to affect heart rhythm) impacts the heart's electrical activity in people with insulin-resistant type 2 diabetes. Researchers will measure changes in heart tracings (ECGs)…
Phase: NA • Sponsor: Richmond Pharmacology Limited • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Liver damage study in head and neck cancer abandoned after just 2 patients
Knowledge-focused TerminatedThis study aimed to find out how often liver fibrosis and cirrhosis occur in people with head and neck cancer, since tobacco and alcohol are risk factors for both. Researchers planned to check liver health using exams and imaging. However, the study was stopped early after only 2…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Alcohol and cirrhosis: can a quick test spot brain problems?
Knowledge-focused TerminatedThis study aimed to see if a short test called BEARNI could detect alcohol-related cognitive impairments (like memory and thinking problems) in people with alcoholic cirrhosis. The researchers planned to enroll patients with cirrhosis, but the study was stopped early after only o…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New sickle cell drug pociredir enters early human testing
Knowledge-focused TerminatedThis early-stage study is testing a new drug called pociredir in 24 adults with sickle cell disease. Researchers want to see how the drug moves through the body and whether taking it with food changes its effects. The goal is to gather safety and dosing information, not to treat …
Phase: PHASE1 • Sponsor: Fulcrum Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a common virus trigger thyroid troubles?
Knowledge-focused TerminatedThis study investigated whether polyomaviruses (a type of common virus) are found more often in people with autoimmune thyroiditis or goiters. Researchers compared virus presence in blood, urine, and thyroid tissue from 49 patients undergoing thyroid surgery. The goal was to see …
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused TerminatedThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Phase: NA • Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Tiny nerves may explain chronic cough in diabetes
Knowledge-focused TerminatedThis study looked at whether people with type 2 diabetes who have a chronic cough also have damage to small nerves in their skin. Researchers compared diabetic patients with and without chronic cough using nerve tests and skin biopsies. The study was terminated early with only 7 …
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can pictures help patients understand research better?
Knowledge-focused TerminatedThis study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Pancreatic cancer gene study targets muscle wasting
Knowledge-focused TerminatedThis pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at …
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Heartburn drug tested against pancreatic cancer in early trial
Knowledge-focused TerminatedThis early-phase study tested whether high doses of omeprazole, a common heartburn medication, could safely change certain markers in pancreatic tumors. The trial planned to enroll 25 patients with exocrine pancreatic cancer who were scheduled for surgery. Participants took omepr…
Phase: EARLY_PHASE1 • Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Yeast study in rare autoimmune disease terminated early
Knowledge-focused TerminatedThis study aimed to compare the types of Candida yeast found in patients with two forms of autoimmune polyendocrinopathy, a rare condition where the immune system attacks multiple glands. Researchers planned to collect samples from the mouth and urine of 7 participants to see how…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Scientists probe hidden danger of low blood sugar in diabetes
Knowledge-focused TerminatedThis study looked at why people with type 1 diabetes often fail to sense dangerously low blood sugar (hypoglycemia). Researchers tested how opioid drugs like morphine and naloxone affect the body's ability to respond to low sugar. The goal was to better understand the problem, no…
Phase: PHASE2 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Blood markers may forecast diabetes cure after gastric bypass
Knowledge-focused TerminatedThis study aimed to find blood and tissue markers that could predict whether obese patients with type 2 diabetes would go into remission after bariatric surgery. Researchers planned to measure 9 specific molecules in blood samples and also collect fat and muscle tissue during sur…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Blood test hope for liver cancer diagnosis
Knowledge-focused TerminatedThis study looked at whether two tiny molecules, called miR-221 and miR-222, can be found in the blood of people with liver cancer. Researchers wanted to see if these molecules could help diagnose the disease without needing a liver biopsy. The study was very small, with only 10 …
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Scientists hunt for hidden cancer genes in young patients
Knowledge-focused TerminatedThis study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Why are people with this rare bone disorder prone to diabetes?
Knowledge-focused TerminatedThis pilot study aims to understand why people with pseudohypoparathyroidism type 1A (PHP1A) have a higher risk of type 2 diabetes. Researchers will measure insulin sensitivity and beta-cell function in 14 participants with PHP1A or related conditions, comparing them to matched h…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Mental health study aims to uncover Long-Term heart risks
Knowledge-focused TerminatedThis study followed 167 adults with mental health issues like anxiety, depression, or sleep problems who visited their primary care doctor. Researchers used health conversations and a blood test to track lifestyle changes and heart disease risks over up to 20 years. The goal was …
Phase: NA • Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Hidden fat lumps may sabotage insulin: new study investigates
Knowledge-focused TerminatedThis study looked at whether small, hard-to-see fat lumps under the skin (called subclinical lipohypertrophy) change how insulin is absorbed in people with diabetes. Researchers planned to enroll 20 adults with type 1 or type 2 diabetes who use insulin and had these hidden lumps.…
Phase: NA • Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Virtual reality could help measure and treat cancer pain, study suggests
Knowledge-focused TerminatedThis study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
When you eat matters: stanford study tests meal timing for better blood sugar and sleep
Knowledge-focused TerminatedThis Stanford study looked at how changing when and what you eat affects blood sugar, body temperature, and sleep in people with prediabetes, type 2 diabetes, and healthy adults. Participants followed different meal-timing schedules, like eating within a 10-hour window starting e…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Spinal tap could replace brain surgery for young tumor patients
Knowledge-focused TerminatedThis study looked at whether a liquid biopsy—testing the fluid around the brain and spinal cord—can find tumor DNA in children and young adults with brain tumors. The goal was to see if this safer, non-surgical test could replace risky tissue biopsies for diagnosis and monitoring…
Sponsor: Pediatric Brain Tumor Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry aims to sharpen liver tumor ablation techniques
Knowledge-focused TerminatedThis study tracked over 1,200 people with liver cancer who received microwave ablation, a procedure that uses heat to destroy tumors. Researchers collected data over 5 years to see how well the ablation worked and how long patients lived. The goal was to create better guidelines …
Sponsor: Ethicon, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Vaccine study aims to unlock secrets of immune memory
Knowledge-focused TerminatedThis study looked at how the hepatitis B vaccine triggers immune cells called B cells to form germinal centers, where antibodies become stronger. Researchers wanted to understand if memory B cells return to these centers after a booster shot. The goal was to learn how to design b…
Phase: PHASE4 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Liver impairment study for cancer drug tazemetostat halted early
Knowledge-focused TerminatedThis study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …
Phase: PHASE1 • Sponsor: Epizyme, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Gut bugs linked to bone loss in parathyroid disease
Knowledge-focused TerminatedThis study looked at whether the types of bacteria in the gut can predict bone loss in people with primary hyperparathyroidism, a condition where the parathyroid glands produce too much hormone. Researchers planned to analyze gut bacteria and immune system markers in 25 patients …
Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Gut microbiome study in kids with autoimmune diseases ends early
Knowledge-focused TerminatedThis study aimed to compare the gut bacteria of children newly diagnosed with juvenile idiopathic arthritis, type 1 diabetes, or inflammatory bowel disease with those of their healthy siblings. Researchers wanted to see if differences in gut microbes and diet could explain why so…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Ovarian cancer study reveals hidden struggles of patients and caregivers
Knowledge-focused TerminatedThis study looked at how platinum-resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers surveyed 24 patients and their caregivers using questionnaires to measure symptoms, daily challenges, and overall well-being. The goal wa…
Sponsor: PeriPharm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Ovarian cancer immune cells under microscope in terminated study
Knowledge-focused TerminatedThis study aimed to understand how immune cells in the blood, abdominal fluid, and tumor tissue change in women with advanced ovarian or fallopian tube cancer before and after chemotherapy. Researchers collected samples from 36 women to count different types of immune cells. The …
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Radiation therapy study seeks immune clues in blood
Knowledge-focused TerminatedThis study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Small study tests blood sugar targets to prevent lows during exercise in type 1 diabetes
Knowledge-focused TerminatedThis study looked at people with type 1 diabetes who use do-it-yourself automated insulin delivery (DIY-AID) systems. Researchers wanted to find the best blood glucose target to set 60 minutes before moderate aerobic exercise (like cycling) to keep blood sugar stable and avoid da…
Phase: NA • Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New test may expand olaparib benefits to more ovarian cancer patients
Knowledge-focused TerminatedThis study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Free diabetes classes for latinos aim to uncover health barriers
Knowledge-focused TerminatedThis study looked at Latino adults with diabetes who attended free education classes. Researchers collected information about their health habits, blood sugar levels, and barriers to medical care. The goal was to better understand the needs of this community, not to test a new tr…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New liver tests aim to better predict outcomes in End-Stage disease
Knowledge-focused TerminatedThis study tested whether a new type of liver function test using a substance called cholate could better assess the severity of liver disease in people with end-stage liver disease. The goal was to improve how doctors predict outcomes and guide treatment. The study included 103 …
Phase: PHASE2 • Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Diabetes Drug's heart benefits probed in tiny, terminated study
Knowledge-focused TerminatedThis study aimed to see how dapagliflozin, a diabetes drug, affects blood vessel health in people with type 2 diabetes. Researchers planned to measure blood pressure and other markers of vascular function. However, the trial was terminated early and only enrolled 4 participants, …
Phase: PHASE4 • Sponsor: Boston University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Can your personality change your diabetes genes?
Knowledge-focused TerminatedThis study looked at whether people with type 1 or type 2 diabetes who have a 'Type A' (impatient, proactive) or 'Type B' (calm, slow) personality show different genetic markers linked to inflammation and stress. Researchers planned to collect blood samples and have participants …
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Diabetes drug may alter your taste buds and food desires
Knowledge-focused TerminatedThis study looked at how the diabetes medication Liraglutide (Victoza) affects taste, food cravings, and eating habits in people with type 2 diabetes who are overweight. Researchers compared three groups: patients starting Liraglutide, diabetic patients not on the drug, and healt…
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused TerminatedThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Cystic fibrosis study aims to build a research database, not test a cure
Knowledge-focused TerminatedThis study is for people with cystic fibrosis and their family members. Its goal is to collect medical information and biological samples during regular clinic visits. These will be stored and used by researchers to learn more about how cystic fibrosis affects the body and how it…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Hunt for hidden thyroid cancer genes ends early
Knowledge-focused TerminatedThis study looked for new genes that might increase the risk of developing differentiated thyroid cancer. Researchers planned to analyze the complete DNA of people with thyroid cancer and their family members. The study was stopped early and involved 34 participants.
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Liver transplant study aims to predict outcomes by measuring frailty
Knowledge-focused TerminatedThis study looked at whether simple tests of frailty—like grip strength, walking speed, and weight loss—can predict how well liver transplant patients do before and after surgery. Researchers planned to follow 300 adults with end-stage liver disease who were waiting for a transpl…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Liquid biopsy study halted: did it help guide cancer care?
Knowledge-focused TerminatedThis study aimed to see if a simple blood test (liquid biopsy) could help doctors make better treatment decisions for people with advanced cancers of the colon, pancreas, or bile duct. Researchers planned to enroll about 130 participants but stopped early with only 16 enrolled. T…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Early eating study for diabetes ends early
Knowledge-focused TerminatedThis study looked at whether eating most calories before 2 PM could help control blood sugar in people with type 2 diabetes. It planned to enroll 10 participants but was terminated after only 2 joined. The goal was to compare early eating with a typical eating pattern over six da…
Phase: NA • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Cancer drug interaction study halted after just one patient
Knowledge-focused TerminatedThis early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused TerminatedThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Cancer tissue bank launched to unlock secrets of liver tumors
Knowledge-focused TerminatedThis study aimed to create a registry of tissue and blood samples from 1,000 patients undergoing surgery or biopsy for liver or bile duct tumors. The samples were stored for future research to better understand these cancers and develop new treatments. The study was terminated ea…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Hepatitis c blood study halted early: what it means
Knowledge-focused TerminatedThis study aimed to see how often people with chronic hepatitis C have a blood condition called monoclonal B-cell lymphocytosis (MBL), and whether treating hepatitis C affects MBL. Researchers planned to enroll 29 participants and compare blood samples before and after hepatitis …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists tap cancer fluids for clues to better treatments
Knowledge-focused TerminatedThis study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Timing delivery for gestational diabetes: What's the safest week?
Knowledge-focused TerminatedThis study aimed to find the best time (between 37 and 39 weeks of pregnancy) to deliver babies of women with poorly controlled gestational diabetes. Researchers planned to enroll up to 3,450 pregnant women but stopped early with 304 participants. The goal was to see which delive…
Phase: NA • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can a Stick-On sensor replace finger pricks before surgery?
Knowledge-focused TerminatedThis pilot study tested whether continuous glucose monitors (CGMs) could be used in the days before and after surgery to track blood sugar in people with diabetes. Researchers placed a CGM sensor on 22 patients during a preoperative visit and compared its readings to standard fin…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Liver cancer study seeks immune clues to immunotherapy success
Knowledge-focused TerminatedThis study aimed to see if certain immune cells in the blood could predict which patients with advanced liver cancer would benefit from a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these cells before and after starting treatm…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
NASH registry study aims to map disease in chinese patients
Knowledge-focused TerminatedThis study was designed to collect information about Chinese patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Researchers planned to track how the disease is diagnosed and treated in real-world clinics, and to understand patients' knowledge and beliefs about …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New urine test could reveal if diabetes patients are taking their pills
Knowledge-focused TerminatedThis study aimed to see if a new urine test can accurately tell whether people with type 2 diabetes are taking their medications as prescribed. Researchers planned to compare the urine test results with standard methods like questionnaires and pharmacy records in 90 participants.…
Sponsor: University of Leicester • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Tablet teaching for diabetes: a High-Tech hope for new patients?
Knowledge-focused TerminatedThis study tested whether using a bedside tablet with interactive education modules helps people newly diagnosed with type 1 diabetes learn more than standard paper-based materials. The trial planned to enroll 28 patients but was terminated early. Researchers measured diabetes kn…
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
PCOS hormone study halted early – what it means for IVF
Knowledge-focused TerminatedThis study looked at whether high levels of male hormones (hyperandrogenism) lower the chance of IVF success in women with PCOS. Researchers planned to track 32 women aged 18–39, but the study was terminated early. The goal was to see if these hormones affect pregnancy rates afte…
Sponsor: Clinique Ovo • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New survey aims to better measure life quality in pituitary tumor patients
Knowledge-focused TerminatedThis study tested a new questionnaire called Prolac-10 to see if it can accurately measure quality of life in people with prolactinoma (a type of pituitary tumor) who are starting medical treatment. Only 8 people took part before the study was stopped early. The goal was to check…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Heart ultrasound showdown: trained generalists vs. experts in liver patients
Knowledge-focused TerminatedThis study looked at whether gastroenterologists (liver doctors) who are not heart ultrasound specialists, but received standard training, could measure heart function as accurately as experts in patients with severe cirrhosis and swelling. The goal was to see if simple heart ass…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused TerminatedThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New scan could help doctors plan better liver cancer treatments
Knowledge-focused TerminatedThis study tested a special type of scan (SPECT/CT) to see how well it measures liver function in people with liver cancer who are getting radiation or surgery. The goal was to learn if this scan can help doctors see which parts of the liver are working well before, during, and a…
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Can a fitness watch help kids with diabetes get moving?
Knowledge-focused TerminatedThis study looked at whether wearing a Garmin Vivosmart activity tracker could increase physical activity and improve diabetes control in children and young adults (ages 8-21) with Type 1 Diabetes. Participants wore the tracker for a year and completed surveys about their diabete…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
New study checks if sugar sensors work in sick newborns
Knowledge-focused TerminatedThis study looked at how accurate Dexcom G6 continuous glucose monitors are for newborns with hyperinsulinism, a condition causing low blood sugar. One baby wore the sensor on their thigh for 10 days in the NICU. Researchers compared the sensor's readings with standard blood suga…
Sponsor: MemorialCare Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Liver study of cancer drug amcenestrant halted early
Knowledge-focused TerminatedThis early-stage study looked at how the drug amcenestrant is processed in the body of women aged 40-75 with mild or moderate liver problems, compared to women with healthy livers. The goal was to understand dosing and safety. However, the trial was terminated before completion, …
Phase: PHASE1 • Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Hepatitis b patients under the microscope: new study observes Real-World treatments
Knowledge-focused TerminatedThis study observed over 1,700 adults with chronic hepatitis B in the US and Canada to understand how the disease progresses and how treatments are used in everyday medical practice. Researchers collected data from both academic and community clinics to build a real-world picture…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:05 UTC
-
Study on arthritis and diabetes link halted early
Knowledge-focused TerminatedThis study looked at whether people with both rheumatoid arthritis and type 2 diabetes have a harder time controlling their diabetes than those with osteoarthritis and diabetes. Researchers planned to follow 176 adults to see how quickly they needed new diabetes treatments. Howev…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
New device aims to sharpen liver tumor ablation
Knowledge-focused TerminatedThis pilot study tested a device called BioTraceIO 360, designed to help doctors plan and monitor procedures that destroy liver tumors using heat. The study planned to enroll 30 people with liver cancer, but only 4 participated before it was stopped early. Researchers looked at w…
Phase: NA • Sponsor: Techsomed Medical Technologies LTD • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:06 UTC
-
New E-Health system aims to keep tabs on chronic patients remotely
Knowledge-focused TerminatedThis pilot study tested an e-health system that uses tele-monitoring, tele-notification, and tele-coaching to help manage adults with at least two chronic conditions like heart failure, COPD, or diabetes. The goal was to see how well the system could detect health problems early.…
Phase: NA • Sponsor: Air Liquide Santé International • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:48 UTC
-
Can two old drugs stop a dangerous diabetes complication?
Knowledge-focused TerminatedThis study tested whether two medications, naloxone (a nasal spray) and diazoxide (an oral pill), could prevent the body from losing its ability to sense low blood sugar—a condition called hypoglycemia unawareness. Only 4 healthy volunteers were enrolled before the trial was stop…
Phase: PHASE4 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:35 UTC
-
Vitamin a booster for Kids' vaccines? small study cut short
Knowledge-focused TerminatedThis early-phase study looked at whether giving vitamin A along with the pneumococcus vaccine (Prevnar) helps children ages 1 to 4 build a stronger immune response. Only 22 healthy kids were enrolled before the study was stopped early. Researchers measured antibody levels in the …
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:15 UTC
-
Herbal medicine safety under the microscope in korean hospitals
Knowledge-focused TerminatedThis study observed women aged 19–80 who were hospitalized for at least two weeks and taking herbal medicines. Researchers tracked liver and kidney function through regular blood tests to see if any injuries occurred. The goal was to better understand the safety profile of these …
Sponsor: Korea Institute of Oriental Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:21 UTC